The Lancet
Author:
Keywords:
Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, EUROPEAN-ORGANIZATION, II TRIAL, ANGIOGENESIS, GEMCITABINE, CARDIOTOXICITY, INHIBITOR, DOCETAXEL, SUNITINIB, IMATINIB, EORTC, Adolescent, Adult, Aged, Antineoplastic Agents, Cross-Over Studies, Disease-Free Survival, Double-Blind Method, Female, Humans, Indazoles, Kaplan-Meier Estimate, Male, Middle Aged, Pyrimidines, Sarcoma, Soft Tissue Neoplasms, Sulfonamides, Treatment Outcome, Young Adult, EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences
Abstract:
Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.